32383-03-2

Usage

Uses

Used in Chemical Synthesis:
6-Chloropyridine-2,3-dicarboxylic acid dimethyl ester is used as a chemical intermediate for the synthesis of various compounds. Its functional groups, including chlorine, carboxylic acid, and ester, make it a versatile building block for creating a range of chemical products.
Used in Pharmaceutical Industry:
6-Chloropyridine-2,3-dicarboxylic acid dimethyl ester is used as a starting material for the development of new pharmaceutical compounds. Its reactivity and functional groups can be utilized to create potential drug candidates with desired therapeutic properties.
Used in Material Science:
6-Chloropyridine-2,3-dicarboxylic acid dimethyl ester is used as a component in the development of new materials with specific properties. Its chemical structure and reactivity can contribute to the creation of advanced materials for various applications, such as electronics, coatings, or adhesives.
Used in Research and Development:
6-Chloropyridine-2,3-dicarboxylic acid dimethyl ester is used as a research compound for studying its chemical properties, reactivity, and potential applications. It can serve as a model compound for understanding the behavior of similar compounds and exploring new synthetic routes or reactions.

Upstream product

• 127437-44-9 6-chloropyridine-2,3-dicarboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 89-00-9 Pyridine-2,3-dicarboxylic acid 
• 605-38-9 dimethyl 2,3-pyridinedicarboxylate 
• 32383-02-1 pyridine-2,3-dicarboxylic acid dimethyl ester N-oxide 

Downstream Products

• 169745-84-0 6-phenylthiopyridine-2,3-dicarboxylic acid dimethyl ester 
• 1445596-32-6 methyl 6-cyclopropyl-3-phenylpicolinate 
• 1445596-33-7 methyl 6-cyclopropyl-3-phenylpicolinate 
• 220001-94-5 6-chloro-2,3-bis(chloromethyl)pyridine 
• 220001-93-4 (6-chloropyridine-2,3-diyl)dimethanol 
• 169745-87-3 2-benzenesulfonyl-5-benzo[1,3]dioxol-5-yl-7-(4-methoxy-phenyl)-5-(2-trimethylsilanyl-ethoxymethoxy)-5H-[1]pyrindine-6-carboxylic acid tert-butyl ester 
• 169745-86-2 5-benzo[1,3]dioxol-5-yl-7-(4-methoxy-phenyl)-2-phenylsulfanyl-5-(2-trimethylsilanyl-ethoxymethoxy)-5H-[1]pyrindine-6-carboxylic acid tert-butyl ester 
• 169745-90-8 5-benzo[1,3]dioxol-5-yl-7-(4-methoxy-phenyl)-2-propylsulfanyl-5-(2-trimethylsilanyl-ethoxymethoxy)-5H-[1]pyrindine-6-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tan protein, such that tan protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tan. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tan protein. Diseases or disorders that result from aggregation or accumulation of tan protein are treated or prevented with compounds and compositions of the present disclosure.

CGRP ANTAGONIST COMPOUNDS

The disclosures herein relate to novel compounds of Formula (1): and salts thereof, wherein A1, A2, Q, X, R1, R2 and R3 are defined herein, and their use in treating, preventing, ameliorating, control

ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE

Disclosed is a substituted nitroimidazole derivative, which is mainly used for treating related diseases caused by mycobacterial infections, such as Mycobacterium tuberculosis, especially being suitable for diseases caused by resistant Mycobacterium tuberculosis.

Boron-Containing Small Molecules as Anti-Inflammatory Agents

Compounds and methods of treating anti-inflammatory conditions are disclosed.

CHEMICAL COMPOUNDS

The invention relates to a novel compound of formula (I) or a stereoisomer, or a racemate or a mixture or a pharmaceutically acceptable salt thereof: wherein: R is phenyl or a 5- or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from S, N and O, such rings may be optionally substituted with n groups Q; Q is selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, SO2CH3 or a group —O[(CR1R2]pQ1; or Q may be a group Q2; Q1 is phenyl, which may be optionally substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, or a group Q2; or corresponds to 2,2-difluoro-benzo[d][1,3]dioxol-4-yl; Q2 is a 5- or 6-membered heteroaryl containing at least one nitrogen atom, which may optionally substituted with n substituents selected from a group consisting of: Cl C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; P is a 6-membered heteroaryl or a 8-1 1 membered bicyclic heteroaryl group, which may be substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; R1 is hydrogen or C1-C3 alkyl; R2 is hydrogen or C1-C3 alkyl; n is 1, 2 or 3; p is 0, 1 or 2; and with the proviso that when R corresponds to phenyl, P is substituted by at least one CF3; processes for the preparation of those compounds, pharmaceutical compositions containing one or more compounds of formula (I) and their use as dual antagonists of the Orexin 1 and Orexin 2 receptors.

CHEMICAL COMPOUNDS

The invention relates to a novel compound of formula (I) or a stereoisomer, or a racemate or a mixture or a pharmaceutically acceptable salt thereof: wherein: R is phenyl or a 5- or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from S, N and O, such rings may be optionally substituted with n groups Q; Q is selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, SO2CH3 or a group -O[(CR1R2]pQ1; or Q may be a group Q2; Q1 is phenyl, which may be optionally substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, or a group Q2; or corresponds to 2,2-difluoro- benzo[d][1,3]dioxol-4-yl; Q2 is a 5- or 6-membered heteroaryl containing at least one nitrogen atom, which may optionally substituted with n substituents selected from a group consisting of: C1 C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; P is a 6-membered heteroaryl or a 8-1 1 membered bicylic heteroaryl group, which may be substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; R1 is hydrogen or C1-C3 alkyl; R2 is hydrogen or C1-C3 alkyl; n is 1, 2 or 3; p is 0, 1 or 2; and with the proviso that when R corresponds to phenyl, P is substituted by at least one CF3; processes for the preparation of those compounds, pharmaceutical compositions containing one or more compounds of formula (I) and their use as dual antagonists of the Orexin 1 and Orexin 2 receptors.

Integrase inhibitor compounds

Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

Structure-activity relationships of 2-substituted 5,7-Diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acids as a novel class of endothelin receptor antagonists

Synthesis and structure-activity relationships of 2-substituted-5,7-diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acids, a novel class of endothelin receptor antagonists, were described. Derivatization of a lead structure 1 (IC50=2.4 nM, 170-fold selectivity) by incorporating a substituent such as an alkyl, alkoxy, alkylthio, or alkylamino group into the 2-position of the cyclopenteno[1,2-b]pyridine skeleton was achieved via the key intermediate 8. Introduction of an alkyl group led to the identification of potent ETA/ETB mixed receptor antagonists, a butyl (2d: IC50=0.21 nM, 52-fold selectivity) and an isobutyl (2f: IC50=0.32 nM, 26-fold selectivity) analogue. In contrast, installment of a primary amino group resulted in ETA selective antagonists, a propylamino 2p (IC50=0.12 nM, 520-fold selectivity) and an isopropylamino 2q (IC50=0.10 nM, 420-fold selectivity) analogue. These results suggested that a substituent at the 2-position of the 5,7-diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acids played a key role in the binding affinity for both ETA and ETB receptors.